Sarah E. Tomassetti, MD
Languages
Education
Fellowship
Degrees
Residency
Contact Information
Phone
Scientific Interests
Dr. Sarah Tomassetti is a hematologist and oncologist who specializes in the treatment of hematologic malignancies with particular interest in the treatment of Hodgkin and Non-Hodgkin lymphomas.
Highlighted Publications
Chen R, Palmer J, Tomassetti S, Popplewell L, Alluin J, Chomchan P, Nademanee A, Sidiqi T, Tsai N, Chen L, Zuo F, Abary R, Cai J, Herrera AF, Rossi JJ, Rosen ST, Forman SJ, Kwak LQ, and Holmberg L. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. Journal of Hematologic Oncology. 2018;11:87.
Sarah Tomassetti and Alex F. Herrera. Update on the role of brentuximab vedotin in classical Hodgkin lymphoma. Therapeutic Advances in Hematology. 2018;9(9):261-272.
Sarah Tomassetti and Robert Chen. The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma. Therapeutic Advances in Hematology. 2019;10.
Merryman R, Carreau NA, Pail O, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Cohen JB, Troxel AB, Diefenbach C, and Armand P. Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Blood 2018; 132(suppl. 1): 1626.
Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner- Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Xia Y, Troxel AB, and Diefenbach C. Checkpoint Blockade May Sensitize Non-Hodgkin Lymphoma to Subsequent Therapy. Blood 2018; 132(suppl. 1): 93.